Shares of Scancell Holdings plc (LON:SCLP – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 13.72 ($0.17) and traded as low as GBX 10.77 ($0.13). Scancell shares last traded at GBX 11.10 ($0.14), with a volume of 100,543 shares trading hands.
Scancell Stock Performance
The firm has a market capitalization of £102.92 million, a price-to-earnings ratio of -1,107.10 and a beta of 0.35. The company has a debt-to-equity ratio of 61.41, a quick ratio of 13.01 and a current ratio of 3.42. The stock’s fifty day moving average is GBX 13.07 and its two-hundred day moving average is GBX 13.73.
About Scancell
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel immunotherapies and vaccines for the treatment of cancer and infectious disease. Its product candidates include SCIB1, an ImmunoBody cancer vaccine that is in Phase II for the treatment of metastatic melanoma; and SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumors, including non-small cell lung cancer.
See Also
- Five stocks we like better than Scancell
- About the Markup Calculator
- Hedge Funds Boost Oil Positions: Is a Major Rally on the Horizon?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Power Play: Japan’s Top Auto Stocks Eye Historic Merger
- The Risks of Owning Bonds
- S&P 500 Earnings Set to Shine: January’s Critical Market Test
Receive News & Ratings for Scancell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell and related companies with MarketBeat.com's FREE daily email newsletter.
